Highlights

  • Stevanato reported third-quarter Revenue growth of 8% to EUR 326.1 million.
  • High-value solutions generated EUR 149.4 million, representing 46% of quarterly revenue.
  • Adjusted EBITDA Margin increased 150 basis points to 27.2% in the third quarter.
  • The company maintained its full-year 2026 revenue and adjusted Earnings guidance ranges.

Higher quarterly sales and a stable annual outlook provided the financial backdrop for Stevanato Group (NYSE: STVN), whose shares rose 10.03% to USD 15.80 on November 13. The company, which supplies pharmaceutical containment and delivery technologies, reported third-quarter 2026 results on November 3. Revenue increased in its biopharmaceutical and diagnostic solutions activities while the engineering Business recorded a decline. The announcement showed how different operations contributed to the consolidated result and highlighted the continued role of high-value products.

Biopharmaceutical Operations Lead Revenue

Third-quarter revenue increased 8% to EUR 326.1 million, with organic revenue also rising 8%. The Biopharmaceutical and Diagnostic Solutions segment generated an 11% Organic Sales increase. This more than offset a 12% decrease in revenue from the Engineering segment. The distinction helps explain the consolidated figure without treating every part of the company as growing at the same pace. Stevanato supplies drug containment and delivery components, diagnostic solutions and related engineering offerings to pharmaceutical, biotechnology and life-sciences customers. Its activities span products and services with different timing and margin profiles.

High-Value Products Retain a Large Share

Revenue from high-value solutions reached EUR 149.4 million, up 1% year over year and on an organic basis. These products represented 46% of total revenue for the quarter. The company also disclosed that therapies involving GLP-1 drugs accounted for approximately 17%–18% of total quarterly revenue. These numbers describe exposure and mix, not a prediction about Demand in coming periods. High-value solutions remained a significant component of the group's sales base even though their rate of growth was slower than that of total revenue for the period.

Earnings and Margins Provide the Counterpart

Gross profit totaled EUR 95.0 million and gross margin was 29.1%. Adjusted EBITDA margin improved by 150 basis points to 27.2%. Diluted Earnings per Share rose 15% to EUR 0.15, while adjusted diluted earnings per share increased 14% to EUR 0.16. These are distinct reported and adjusted earnings figures; the latter should not be substituted for the former. Margin changes also need to be understood alongside the varying performances of the company's product and engineering segments. The reported figures indicate improvements in selected profit measures despite uneven segment revenue trends.

Quarterly diluted earnings per share of EUR 0.15 and adjusted diluted earnings of EUR 0.16 were both higher than the prior-year equivalents. The company identified a consolidated improvement in adjusted EBITDA margin despite the decline in its engineering operation. That combination gives the quarterly release two separate points of emphasis: the relative contribution of different segments to revenue, and the efficiency reflected in group adjusted operating profitability.

Annual Targets Stay Unchanged

Stevanato retained its full-year 2026 guidance for revenue between EUR 1.260 billion and EUR 1.280 billion. The company continued to expect adjusted EBITDA of EUR 335.0 million–EUR 345.2 million and adjusted diluted earnings per share of EUR 0.60–EUR 0.62. These ranges were management expectations as of the November 3 announcement, not achieved results. Subsequent reports will show whether the biopharmaceutical segment continues to offset engineering weakness and how the high-value sales mix develops. The November 13 stock gain adds market context but does not establish an individual cause for the movement.